These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22544675)

  • 41. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
    Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
    Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
    Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
    Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
    Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metronomic chemotherapy: an antiangiogenic scheduling.
    Laquente B; Viñals F; Germà JR
    Clin Transl Oncol; 2007 Feb; 9(2):93-8. PubMed ID: 17329220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All.
    André N; Orbach D; Pasquier E
    Trends Cancer; 2020 Oct; 6(10):819-828. PubMed ID: 32601045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
    Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
    Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metronomic chemotherapy: A relook at its basis and rationale.
    Rajasekaran T; Ng QS; Tan DS; Lim WT; Ang MK; Toh CK; Chowbay B; Kanesvaran R; Tan EH
    Cancer Lett; 2017 Mar; 388():328-333. PubMed ID: 28003122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
    Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.
    Wichmann V; Eigeliene N; Saarenheimo J; Jekunen A
    Acta Oncol; 2020 Jul; 59(7):775-785. PubMed ID: 32275176
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.
    Bocci G; Tuccori M; Emmenegger U; Liguori V; Falcone A; Kerbel RS; Del Tacca M
    Ann Oncol; 2005 Aug; 16(8):1243-52. PubMed ID: 15905308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.
    Benzekry S; Hahnfeldt P
    J Theor Biol; 2013 Oct; 335():235-44. PubMed ID: 23850479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
    El-Arab LR; Swellam M; El Mahdy MM
    J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
    Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer.
    Koltai T; Cardone RA; Reshkin SJ
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical implications of antiangiogenic therapies.
    Hudis CA
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.